Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT

Running, not enrolling · Phase 1

Conditions studied: Prostate Cancer

In brief

The purpose of this study is to learn if the study drug, \[225Ac\]Ac-PSMA-R2, is safe and tolerable, and has anti-tumor activity in treated patients.

Key facts

Study ID

NCT05983198

Run by

Novartis Pharmaceuticals

People needed

33

Starts

2023-11-07

Expected to finish

2031-03-04

Last updated by the study team

2026-06-29

Who can join

Age: 18 and older, up to 100. Sex: male. Healthy volunteers: not accepted.

Where it is running

• BAMF Health — Grand Rapids, Michigan, United States
• Mayo Clinic Rochester — Rochester, Minnesota, United States
• Novartis Investigative Site — Darlinghurst, New South Wales, Australia
• Novartis Investigative Site — Montreal, Quebec, Canada
• Novartis Investigative Site — Dijon, Cote D Or, France
• Novartis Investigative Site — Clermont-Ferrand, France
• Novartis Investigative Site — Lyon, France
• Novartis Investigative Site — Nantes, France
• Novartis Investigative Site — Saint-Herblain, France
• Novartis Investigative Site — Vandœuvre-lès-Nancy, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.